Assessing the burden of HPV-related cancers in Appalachia

Paul L. Reiter; James L. Fisher; Alana G. Hudson; Thomas C. Tucker; Jesse J. Plascak; Electra D. Paskett

doi:10.4161/hv.22389

Assessing the burden of HPV-related cancers in Appalachia

Paul L. Reiter
, James L. Fisher
, Alana G. Hudson
, Thomas C. Tucker
, Jesse J. Plascak
, Electra D. Paskett

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Appalachia is a geographic region with existing cancer disparities, yet little is known about its burden of HPV-related cancers outside of cervical cancer. We assessed the burden of HPV-related cancers in three Appalachian states and made comparisons to non-Appalachian regions. We examined 1996-2008 cancer registry data for Ohio, Kentucky, West Virginia and the Surveillance, Epidemiology and End Results (SEE R) 9 program. For each gender, we calculated age-adjusted incidence rates per 100,000 population for each HPV-related cancer type (cervical, vaginal, vulvar, penile, anal and oral cavity and pharyngeal cancers) and all HPV-related cancers combined. Incidence rates among females for all HPV-related cancers combined were higher in Appalachian Kentucky [24.6 (95% CI: 23.5-25.7)], West Virginia [22.8 (95% CI: 22.0- 23.6)] and Appalachian Ohio [21.9 (95% CI: 21.0-22.8)] than SEE R 9 [18.8 (95% CI: 18.6-19.0)]. Similar disparities were found among females when examining cervical and vulvar cancers separately. Among males, Appalachian [21.3 (95% CI: 20.2- 22.4)] and non-Appalachian [21.9 (95% CI: 21.2-22.7)] Kentucky had higher incidence rates for all HPV-related cancers combined than SEE R 9 [18.3 (95% CI: 18.1-18.6)]. The incidence rate of all HPV-related cancers combined was higher among males from Appalachian Ohio compared with those from non-Appalachian Ohio [17.6 (95% CI: 16.8-18.5) vs. 16.3 (95% CI: 16.0-16.6)]. Our study suggests that HPV-related cancer disparities exist in Appalachia beyond the known high cervical cancer incidence rates. These results have important public health implications by beginning to demonstrate the potential impact that widespread HPV vaccination could have in Appalachia.

Original language	English
Pages (from-to)	90-96
Number of pages	7
Journal	Human Vaccines and Immunotherapeutics
Volume	9
Issue number	1
DOIs	https://doi.org/10.4161/hv.22389
State	Published - Jan 2013

Bibliographical note

Funding Information:
Data used in this presentation were provided by the Kentucky and West Virginia Cancer Registries and the Ohio Cancer Incidence Surveillance System. This study was supported by the National Cancer Institute at the National Institutes of Health [P50CA105632, P30CA016058 and U01CA114622 (Appalachia Community Cancer Network)] and the Centers for Disease Control and Prevention (cooperative agreement number U58/ CCU000768). The opinions expressed in this paper are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention.

Funding

Data used in this presentation were provided by the Kentucky and West Virginia Cancer Registries and the Ohio Cancer Incidence Surveillance System. This study was supported by the National Cancer Institute at the National Institutes of Health [P50CA105632, P30CA016058 and U01CA114622 (Appalachia Community Cancer Network)] and the Centers for Disease Control and Prevention (cooperative agreement number U58/ CCU000768). The opinions expressed in this paper are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention.

Funders	Funder number
National Institutes of Health (NIH)
Centers for Disease Control and Prevention	U58/ CCU000768
National Childhood Cancer Registry – National Cancer Institute	P50CA105632, U01CA114622, P30CA016058

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Appalachia
Cancer
Disparities
HPV
Human papillomavirus

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.4161/hv.22389

Cite this

@article{b04ab35e38dd4f8e81b82f0e8736e9d6,

title = "Assessing the burden of HPV-related cancers in Appalachia",

abstract = "Appalachia is a geographic region with existing cancer disparities, yet little is known about its burden of HPV-related cancers outside of cervical cancer. We assessed the burden of HPV-related cancers in three Appalachian states and made comparisons to non-Appalachian regions. We examined 1996-2008 cancer registry data for Ohio, Kentucky, West Virginia and the Surveillance, Epidemiology and End Results (SEE R) 9 program. For each gender, we calculated age-adjusted incidence rates per 100,000 population for each HPV-related cancer type (cervical, vaginal, vulvar, penile, anal and oral cavity and pharyngeal cancers) and all HPV-related cancers combined. Incidence rates among females for all HPV-related cancers combined were higher in Appalachian Kentucky [24.6 (95\% CI: 23.5-25.7)], West Virginia [22.8 (95\% CI: 22.0- 23.6)] and Appalachian Ohio [21.9 (95\% CI: 21.0-22.8)] than SEE R 9 [18.8 (95\% CI: 18.6-19.0)]. Similar disparities were found among females when examining cervical and vulvar cancers separately. Among males, Appalachian [21.3 (95\% CI: 20.2- 22.4)] and non-Appalachian [21.9 (95\% CI: 21.2-22.7)] Kentucky had higher incidence rates for all HPV-related cancers combined than SEE R 9 [18.3 (95\% CI: 18.1-18.6)]. The incidence rate of all HPV-related cancers combined was higher among males from Appalachian Ohio compared with those from non-Appalachian Ohio [17.6 (95\% CI: 16.8-18.5) vs. 16.3 (95\% CI: 16.0-16.6)]. Our study suggests that HPV-related cancer disparities exist in Appalachia beyond the known high cervical cancer incidence rates. These results have important public health implications by beginning to demonstrate the potential impact that widespread HPV vaccination could have in Appalachia.",

keywords = "Appalachia, Cancer, Disparities, HPV, Human papillomavirus",

author = "Reiter, \{Paul L.\} and Fisher, \{James L.\} and Hudson, \{Alana G.\} and Tucker, \{Thomas C.\} and Plascak, \{Jesse J.\} and Paskett, \{Electra D.\}",

note = "Funding Information: Data used in this presentation were provided by the Kentucky and West Virginia Cancer Registries and the Ohio Cancer Incidence Surveillance System. This study was supported by the National Cancer Institute at the National Institutes of Health [P50CA105632, P30CA016058 and U01CA114622 (Appalachia Community Cancer Network)] and the Centers for Disease Control and Prevention (cooperative agreement number U58/ CCU000768). The opinions expressed in this paper are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention.",

year = "2013",

month = jan,

doi = "10.4161/hv.22389",

language = "English",

volume = "9",

pages = "90--96",

number = "1",

}

TY - JOUR

T1 - Assessing the burden of HPV-related cancers in Appalachia

AU - Reiter, Paul L.

AU - Fisher, James L.

AU - Hudson, Alana G.

AU - Tucker, Thomas C.

AU - Plascak, Jesse J.

AU - Paskett, Electra D.

N1 - Funding Information: Data used in this presentation were provided by the Kentucky and West Virginia Cancer Registries and the Ohio Cancer Incidence Surveillance System. This study was supported by the National Cancer Institute at the National Institutes of Health [P50CA105632, P30CA016058 and U01CA114622 (Appalachia Community Cancer Network)] and the Centers for Disease Control and Prevention (cooperative agreement number U58/ CCU000768). The opinions expressed in this paper are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention.

PY - 2013/1

Y1 - 2013/1

N2 - Appalachia is a geographic region with existing cancer disparities, yet little is known about its burden of HPV-related cancers outside of cervical cancer. We assessed the burden of HPV-related cancers in three Appalachian states and made comparisons to non-Appalachian regions. We examined 1996-2008 cancer registry data for Ohio, Kentucky, West Virginia and the Surveillance, Epidemiology and End Results (SEE R) 9 program. For each gender, we calculated age-adjusted incidence rates per 100,000 population for each HPV-related cancer type (cervical, vaginal, vulvar, penile, anal and oral cavity and pharyngeal cancers) and all HPV-related cancers combined. Incidence rates among females for all HPV-related cancers combined were higher in Appalachian Kentucky [24.6 (95% CI: 23.5-25.7)], West Virginia [22.8 (95% CI: 22.0- 23.6)] and Appalachian Ohio [21.9 (95% CI: 21.0-22.8)] than SEE R 9 [18.8 (95% CI: 18.6-19.0)]. Similar disparities were found among females when examining cervical and vulvar cancers separately. Among males, Appalachian [21.3 (95% CI: 20.2- 22.4)] and non-Appalachian [21.9 (95% CI: 21.2-22.7)] Kentucky had higher incidence rates for all HPV-related cancers combined than SEE R 9 [18.3 (95% CI: 18.1-18.6)]. The incidence rate of all HPV-related cancers combined was higher among males from Appalachian Ohio compared with those from non-Appalachian Ohio [17.6 (95% CI: 16.8-18.5) vs. 16.3 (95% CI: 16.0-16.6)]. Our study suggests that HPV-related cancer disparities exist in Appalachia beyond the known high cervical cancer incidence rates. These results have important public health implications by beginning to demonstrate the potential impact that widespread HPV vaccination could have in Appalachia.

AB - Appalachia is a geographic region with existing cancer disparities, yet little is known about its burden of HPV-related cancers outside of cervical cancer. We assessed the burden of HPV-related cancers in three Appalachian states and made comparisons to non-Appalachian regions. We examined 1996-2008 cancer registry data for Ohio, Kentucky, West Virginia and the Surveillance, Epidemiology and End Results (SEE R) 9 program. For each gender, we calculated age-adjusted incidence rates per 100,000 population for each HPV-related cancer type (cervical, vaginal, vulvar, penile, anal and oral cavity and pharyngeal cancers) and all HPV-related cancers combined. Incidence rates among females for all HPV-related cancers combined were higher in Appalachian Kentucky [24.6 (95% CI: 23.5-25.7)], West Virginia [22.8 (95% CI: 22.0- 23.6)] and Appalachian Ohio [21.9 (95% CI: 21.0-22.8)] than SEE R 9 [18.8 (95% CI: 18.6-19.0)]. Similar disparities were found among females when examining cervical and vulvar cancers separately. Among males, Appalachian [21.3 (95% CI: 20.2- 22.4)] and non-Appalachian [21.9 (95% CI: 21.2-22.7)] Kentucky had higher incidence rates for all HPV-related cancers combined than SEE R 9 [18.3 (95% CI: 18.1-18.6)]. The incidence rate of all HPV-related cancers combined was higher among males from Appalachian Ohio compared with those from non-Appalachian Ohio [17.6 (95% CI: 16.8-18.5) vs. 16.3 (95% CI: 16.0-16.6)]. Our study suggests that HPV-related cancer disparities exist in Appalachia beyond the known high cervical cancer incidence rates. These results have important public health implications by beginning to demonstrate the potential impact that widespread HPV vaccination could have in Appalachia.

KW - Appalachia

KW - Cancer

KW - Disparities

KW - HPV

KW - Human papillomavirus

UR - https://www.scopus.com/pages/publications/84874736426

UR - https://www.scopus.com/pages/publications/84874736426#tab=citedBy

U2 - 10.4161/hv.22389

DO - 10.4161/hv.22389

M3 - Article

C2 - 23143774

AN - SCOPUS:84874736426

SN - 2164-5515

VL - 9

SP - 90

EP - 96

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 1

ER -

Assessing the burden of HPV-related cancers in Appalachia

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this